Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

KBIO $34.83 8.2000 +30.79%
CLVS $32.22 3.0600 +10.49%
TCON $11.26 1.0100 +9.85%
CALA $8.32 0.6200 +8.05%
DRNA $13.20 0.9400 +7.67%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

XBIT $7.90 -0.6900 -8.03%
OHRP $4.43 -0.3400 -7.13%
MNKD $2.08 -0.1100 -5.02%
PVCT $0.43 -0.0190 -4.22%
THLD $3.67 -0.1300 -3.42%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 888 | 889 | 890 | 891 | 892 | 893 | 894 | 895 | 896 | 897 | Next > | Last >>

bioTheranostics’ CancerTYPE ID® Shows High Accuracy in a Multi-Site Validation Study and Improved Performance Compared with the Standard of Care in Metastatic Tumor Diagnosis

(Yahoo! Finance) June 1, 2012 - bioTheranostics, Inc., developer of innovative oncology diagnostic tests and solution provider for metastatic cancer, today announced findings from two studies showing high diagnostic accuracy for CancerTYPE ID® in determining the primary tumor site in high-grade, metastatic tumors.
read article 

Quest Diagnostics Launches New Molecular Test Panel for Enhanced Thyroid Cancer Detection

(Sacramento Bee) June 1, 2012 - Results of a study of the test panel to be unveiled at the 2012 ASCO Annual Meeting on June 4; new test may reduce risk of surgical removal of healthy thyroids for some patients.
read article 

Omacetaxine Mepesuccinate Shows Activity in Chronic Myeloid Leukemia Patients Who Have Become Resistant to or Intolerant of Prior Tyrosine Kinase Inhibitors (TKIs) (1,2,3)

(Pittsburgh Business Times) June 1, 2012 - Teva Oncology presented two secondary analyses today featuring omacetaxine mepesuccinate, an investigational, first-in-class cephalotaxine that functions as a protein synthesis inhibitor at the American Society of Clinical Oncology Annual Meeting, June 1-5, 2012, Chicago.
read article 

Puma Biotechnology Presents Positive PB272 Clinical Data at ASCO 2012 Annual Meeting

(TheStreet) June 2, 2012 - Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that results from an ongoing Phase I clinical trial of its lead drug candidate PB272 (neratinib) given in combination with the anticancer drugs paclitaxel and trastuzumab in patients with metastatic HER-2 positive breast cancer were presented at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting.
read article 

Oncothyreon Announces Presentation of PX-866 Clinical Data at American Association of Clinical Oncology Annual Meeting

(CNBC) June 2, 2012 - Oncothyreon Inc. today announced that data from two clinical trials of PX-866, a pan-isoform phosphatidylinositol-3-kinase (PI-3K) inhibitor, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Chicago.
read article 

Cabozantinib Demonstrates Encouraging Activity in Patients with Heavily Pretreated Metastatic Renal Cell Carcinoma

(Yahoo! Finance) June 2, 2012 - Exelixis, Inc. today reported positive updated interim data from a cohort of heavily pretreated patients with metastatic refractory renal cell carcinoma (RCC) participating in an ongoing phase 1b trial of cabozantinib.
read article 

Cabozantinib Demonstrates Evidence of Anti-Tumor Effects in Heavily Pretreated Patients With Hepatocellular Carcinoma

(MarketWatch) June 2, 2012 - Exelixis, Inc. today reported positive updated interim data from the cohort of hepatocellular carcinoma (HCC) patients participating in the ongoing phase 2 randomized discontinuation trial (RDT) of cabozantinib.
read article 

Cyclacel Presents New Phase 2 Data of Sapacitabine for MDS at ASCO Annual Meeting

(NASDAQ) June 1, 2012 - Results highlight sapacitabine's activity in MDS and potential role as second-line therapy after treatment failure of hypomethylating agents.
read article 

Clinical Trial at The Cancer Institute of New Jersey Studies Combination of Vaccine and Hormone Therapy in Treatment of Prostate Cancer

(CINJ) June 1, 2012 - Investigators at The Cancer Institute of New Jersey (CINJ) have partnered with the National Cancer Institute (NCI) and launched a clinical trial examining the effectiveness of a combined vaccine and hormone treatment for prostate cancer that is resistant to hormone therapy and not visible on imaging tests such as a CT scan and a bone scan.
read press release 

Seattle Genetics Announces ADCETRIS® Clinical Data to be Reported in Multiple Presentations at ASCO Annual Meeting

(4-traders) June 2, 2012 - 70 percent objective response rate in retreatment trial; multiple objective responses observed in CD30-positive non-Hodgkin lymphoma patients, including four of seven patients with diffuse large B-cell lymphoma; first report of CD30 expression from comprehensive screening in broad range of non-lymphoma malignancies.
read article 

Positive Phase 2 Study Results for Tivantinib in Previously Treated Hepatocellular Carcinoma to Be Presented at ASCO

(TheStreet) June 2, 2012 - Significant improvements in time to progression (TTP) and overall survival (OS) observed in patients whose tumors were MET-high; hepatocellular carcinoma (HCC) is the most common primary liver cancer and on the rise worldwide; phase 3 study among previously treated HCC patients with MET-high tumors is currently being planned with tivantinib.
read article 

Fox Chase Cancer Center Researchers Find That Accelerated Chemotherapy Given Before Surgery Shows Benefit For Patients With Muscle-Invasive Bladder Cancer

(Fox Chase) June 2, 2012 - For some patients with muscle-invasive bladder cancer, treatment may begin before they undergo cystectomy, or surgical removal of the bladder.
read press release 

Fox Chase Researchers Find That Combination Treatment With Lapatinib and Pazopanib Does Not Improve Outcomes For Patients With Inflammatory Breast Cancer

(Fox Chase) June 2, 2012 - Inflammatory breast cancer is a very aggressive type of cancer associated with early metastasis and poor survival rates, and the prognosis is even worse for patients with tumors expressing the ErbB2 receptor.
read press release 

Medivation and Astellas Announce Enzalutamide Data Relating to Quality of Life Measures and Extension of Time to First Skeletal-Related Event

(MarketWatch) June 2, 2012 - Medivation Inc. and Astellas Pharma Inc. announced data for enzalutamide (formerly MDV3100), an investigational, oral, androgen receptor signaling inhibitor, relating to the secondary endpoints of health-related quality of life (QOL) and time to first skeletal-related event in men with castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy.
read article 

Long-Term Side Effects Key When Cancer Patients Choose Drugs

(Yahoo! News/HealthDay News) June 2, 2012 - Although doctors may not see a big difference between the two U.S. Food and Drug Administration-approved drugs pazopanib (Votrient) and sunitinib (Sutent) for the long-term treatment of kidney cancer that has metastasized (spread to other organs), researchers from France found that patients felt Votrient left them less fatigued and with a better quality of life, according to the study.
read article 

Leukemia Survival: The Younger You Are, the Better Your Chances

(ABC News) June 2, 2012 - In general, the prognosis for all of these young patients is good, with more than 85 percent still alive after five years. But for some reason, adolescents and teens don't seem to fare as well as their younger counterparts. How much worse they fared was not really known until today.
read article 

J&J Scores Big With Prostate Cancer Pill

(TheStreet) June 2, 2012 - Johnson & Johnson's Zytiga improved survival in "pre-chemo" prostate cancer patients by 33% and more than doubled the time before cancer worsened compared to control, according to results from a phase III study to be presented today at the American Society of Clinical Oncology (ASCO) annual meeting.
read article 

Roche Cancer Drug Avastin Slows Ovarian Cancer Progression - Study

(Fox Business/Dow Jones Newswires) June 2, 2012 - Adding the cancer drug Avastin to a treatment regimen for women with advanced ovarian cancer helped extend the time before the disease progressed, according to a new study that will be presented Saturday.
read article 

Bristol Immune Drug Shows Promise in Three Cancers

(Reuters) June 2, 2012 - An experimental Bristol-Myers Squibb drug helped shrink tumors in patients with advanced melanoma, kidney and lung cancers in a preliminary trial, raising hopes for yet another drug that can wake up the immune system and train it to attack cancer cells.
read article 

Studies Feature New Targeted Therapies for Patients with Hard-to-Treat Cancers

(ASCO) June 2, 2012 - New studies highlighting treatment advances in platinum resistant ovarian cancer patients; promising results in a targeted immune therapy; survival trends among child and young adult leukemia patients; and analysis of patient preference for treatment in a clinical trial were released today at a press briefing at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO).
read press release 

Study Finds Restricted Access to Sales Reps Impedes Physician Knowledge of New Safety Information

(PhRMA/The Catalyst blog) June 1, 2012 - Yesterday, someone brought to my attention a really interesting study in The Journal of Clinical Hypertension. It evaluated how much the prescribing decisions of physicians are influenced by the information provided to them by biopharmaceutical company sales representatives.
read article 

Global Cancer Cases Could Rise 75% by 2030

(San Francisco Chronicle/Associated Press) May 31, 2012 - Global cancer cases are projected to rise 75 percent by 2030, in part because many other diseases are being stamped out and more developing countries are adopting Western lifestyles linked to cancer, international cancer experts reported.
read article 

WebMD Names New CEO

(Wall Street Journal) June 1, 2012 - WebMD named Cavan M. Redmond chief executive, ending a search that began in January after the abrupt resignation of the health-information provider's former chief.
read article (paid subscription required) 

Bristol Urges Combo Hepatitis C Study with Gilead

(Reuters) May 31, 2012 - Bristol-Myers Squibb Co renewed calls for biotechnology company Gilead Sciences Inc to test one of its hepatitis C drugs in late-stage trials alongside Bristol's own promising medicine, following impressive results from a mid-stage trial that combined the experimental products.
read article 

Positive Test Boosts Sanofi MS Drug Hopes

(Reuters) June 1, 2012 - Sanofi reported positive results from a late-stage trial of its Aubagio multiple sclerosis drug, bolstering its chances of approval by regulators as it seeks to catch up with a fast-selling oral treatment from rival Novartis.
read article